心肌梗死后强化早期并持续降低非高密度脂蛋白胆固醇与预后:SWEDEHEART登记研究
中位随访5.4年,1年时非HDL-C最低四分位组MACE风险显著低于最高四分位组(HR 0.76,95%CI 0.71-0.81);早期(2个月内)并持续达标者结局风险最低(HR 0.80,95%CI 0.74-0.86)。结果提示心梗后应早期强化降脂并持续达标,而非逐步调整。
要点
- 心梗后2个月和1年非HDL-C最低水平与更优结局相关。
- 2个月内达标并持续维持者结局风险最低(HR 0.80)。
- 逐步降脂策略可能延迟达标并带来潜在危害。
核心结论
- 心肌梗死后2个月和1年时达到的非HDL-C水平越低,结局越好。
- 心梗后2个月内达标并持续维持者风险最低,挑战当前逐步降脂策略。
研究设计与样本
- 在入院、2个月和1年时评估非HDL-C水平及达标(<2.2 mmol/L)时机与结局。
- 中位随访5.4年,观察MACE(死亡、心梗和缺血性卒中)、死亡和非致命性心梗。
主要发现
- 随访期间9549例发生MACE,5427例死亡,3946例发生心梗。
- 1年时非HDL-C最低 vs 最高四分位组MACE长期HR为0.76(95%CI 0.71-0.81)。
- 2个月时非HDL-C水平评估显示短期结果一致,包括1年内早期事件(HR 0.80,95%CI 0.68-0.92)。
- 所有结局均观察到类似结果。
- 早期并持续达标者 vs 早期或晚期达标者结局风险最低(HR 0.80,95%CI 0.74-0.86 vs 两者HR均为0.86,95%CI 0.79-0.93)。
关键数值与推荐
- 非HDL-C治疗目标为<2.2 mmol/L。
- 1年时非HDL-C最低 vs 最高四分位组MACE的HR为0.76(95%CI 0.71-0.81)。
- 2个月时非HDL-C评估的早期事件HR为0.80(95%CI 0.68-0.92)。
- 早期并持续达标者结局HR为0.80(95%CI 0.74-0.86),早期或晚期达标者HR均为0.86(95%CI 0.79-0.93)。
临床怎么用
- 心梗后应尽早强化降低非HDL-C,争取2个月内达标(<2.2 mmol/L)。
- 达标后需持续维持,以降低MACE、死亡和心梗风险。
- 避免逐步调整降脂方案而延迟达标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Non-HDL-C provides an estimate of lipid-associated risk and is a secondary treatment target after myocardial infarction (MI). The aim was to study the relationship between non-HDL-C levels after MI and risk of adverse outcomes. METHODS: From the SWEDEHEART registry, 56 262 patients with MI were included. Outcomes were major adverse cardiovascular event (MACE: death, MI, and ischaemic stroke), death, and non-fatal MI. Non-HDL-C was assessed at admission, 2 months, and 1 year. Target achievement (<2.2 mmol/L) of non-HDL-C, timing thereof, and outcomes were assessed. RESULTS: During median follow-up of 5.4 years, 9549 had MACE, 5427 died, and 3946 had MI. Long-term hazard ratio (HR) for MACE in the lowest vs. the highest quartile of achieved non-HDL-C at 1 year was 0.76 [95% confidence interval (CI) 0.71-0.81]. Short-term results were consistent also when assessing non-HDL-C levels at 2 months, including early events up to 1 year (HR 0.80, 95% CI 0.68-0.92). Similar results were observed for all outcomes. Patients achieving both early and sustained targets had lowest risk of outcomes (HR 0.80, 95% CI 0.74-0.86) vs. patients achieving target early or late (HR for both 0.86, 95% CI 0.79-0.93). CONCLUSIONS: The lowest achieved levels both at 2 months and at 1 year of non-HDL-C were associated with better outcome. The lowest risk was observed when target was achieved within 2 months of MI and sustained thereafter. These findings challenge the current stepwise approach for cholesterol lowering after MI, which inevitably results in delaying goal attainment and possible harm.
引用
- Schubert, Leosdottir, Lindahl, et al. Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry. Eur Heart J. 2024. PMID: 39217499. doi:10.1093/eurheartj/ehae576
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。